Seletracetam, a small molecule SV2A modulator for the treatment of epilepsy.
UCB SA was developing the high-affinity synaptic vesicle glycoprotein 2A ligand, seletracetam, an analog of levetiracetam, for the potential oral treatment of epilepsy. Phase II epilepsy trials were underway, but in July 2007, the company stated that development of seletracetam had been put on hold and it is unknown whether planned phase IIb/III trials will begin.
Pollard
John R
JR
Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA. john.pollard@uphs.upenn.edu
D000818:Animals; D000927:Anticonvulsants / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D010300:Parkinson Disease / Q000188:drug therapy; D011760:Pyrrolidinones / Q000138:chemical synthesis / Q000494:pharmacology / Q000627:therapeutic use*; D013329:Structure-Activity Relationship
D000927:Anticonvulsants; D011760:Pyrrolidinones; C518915:Seletracetam